Expression of Krüppel-like factor 4 in breast cancer tissues and its effects on the proliferation of breast cancer MDA-MB-231 cells

Abstract

Abstract. The aim of the present study was to detect the expression of Krüppel-like factor 4 (KLF4) in breast cancer tissues and to evaluate the effect on the proliferation of breast cancer MDA-MB-231 cells. The expression of KLF4 protein in 239 breast cancer tissues and 40 paracancerous tissues were detected by an immunohistochemical assay, and its correlation with clinical pathological parameters was analyzed. A eukaryotic expression vector, pcDNA3.1-KLF4, was constructed by transient transfection of breast cancer MDA-MB-231 cells with liposomes (experimental group). The untransfected cells and those transfected with empty plasmid pcDNA3.1 were used as the blank and negative control groups, respectively. The expression of the KLF4 gene and protein in the three groups were detected by reverse transcription polymerase chain reaction and western blotting, respectively. Furthermore, the cell proliferative capacity was detected by an MTT assay. The positive expression rate of KLF4 protein in breast cancer tissues (39.0%, 93/239) was significantly lower than that of paracancerous tissues (77.5%, 31/40) (P<0.05). In addition, KLF4 protein expression in breast cancer tissues was correlated with pathological type, histological grade and lymphatic metastasis (P<0.05). KLF4 mRNA and protein were both expressed by the experimental group, but not by the two control groups. Meanwhile, the proliferative capacity of the experimental group was also significantly decreased. A significant decrease in the positive expression rate of KLF4 protein in breast cancer tissues was correlated with several clinical pathological parameters. In addition, transfection of the KLF4 gene inhibited the proliferation of breast cancer cells, suggesting that this gene is important in the onset and progression of this type of cancer.

KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene

“…This, in turn, causes a reversal of the same phenotypes that are typically induced by EGFR. Though KLF4 and EGFR are both widely studied in breast cancer [25,30,31,[47][48][49], this is the first report linking their activities in this disease. Our study suggests that KLF4 expression may dictate the efficacy of EGFR inhibitors in TNBC patients.…”

Cyanidin as potential anticancer agent targeting various proliferative pathways

“…A transcription factor KLF4 has been reported to be an EMT suppressor factor in breast cancer cells. Cyanidin 3‐glucoside (C3G), has increased KLF4 expression in MDA‐MB‐231 as well as MDA‐MB‐468 cells by suppression of FBXO32 expression (Song et al, 2017). For this purpose, MDA‐MB‐231 and MDA‐MB‐468 cell lines were treated with a DMEM medium.…”

Breast cancer stem cells: A review of their characteristics and the agents that affect them

“…KLF4 is differentially expressed in human cancers, and furthermore is bifunctional; it can act as either tumor suppressor or oncogene depending on the tissue, tumor type, and staging 152 . In breast cancer tissues, its protein expression is correlated with pathological type, histological grade, and lymph node involvement; low‐level expression is found in normal breast epithelium, while increased expression is detected in neoplastic cells and before invasion 153 . In estrogen‐dependent breast cancer, KLF4 acts as a tumor suppressor by regulating the transcriptional activity of ERα specifically binding to its DNA‐binding region and preventing it from binding to estrogen response elements in promoter regions 154 .…”